It has been well documented that ALKBH7 could down regulate the expression of its key effectors like UQCRH and HMGN1 and thereby modulate the cell proliferation, lipid metabolism and programmed necrosis in a variety of solid tumors including prostate cancer, ovarian serous carcinoma, hepatocellular carcinoma, breast carcinoma, non-small cell lung cancer and glioblastoma, indicating ALKBH7 may be a potential prognostic maker in a series of solid cancers [15–23]. Here, ALKBH7 is linked to ovarian serous carcinoma.